
    
      This two-stage phase 2 study will determine the safety, tolerability, recommended phase 2
      dose/maximum tolerated dose, preliminary efficacy and predictive/pharmacodynamic biomarkers
      of combined EGFR inhibition (afatinib) and TNF inhibition (prednisone) in previously treated
      NSCLC.
    
  